Skip to main content

Table 2 Baseline characteristics (n = 97)

From: The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole

  N (%)
Median age at diagnosis (range) 63 (20–92)
Histological subtype
 High-grade serous 90 (92.7)
 High-grade endometrioid 5 (5.2)
 Clear cell 2 (2.1)
FIGO stage at diagnosis
 I 7 (7.2)
 II 4 (4.1)
 III 73 (75.3)
 IV 13 (13.4)
ER-status
 Positive 50 (51.5)
 Negative 1 (1)
 Unknown 46 (47.4)
PR-status
 Positive 20 (20.1)
 Negative 11 (11.3)
 Unknown 66 (68)
Primary Surgery status
 Complete debulking 37 (38.1)
 Suboptimal debulking (>1 cm residual disease) 44 (45.3)
 No surgery 16 (16.5)
Platinum-sensitivity
 Platinum-sensitive 39 (40)
 Platinum-resistant 58 (60)
Number of lines of prior chemotherapy
 1 18 (18.6)
 2 15 (15.5)
 3 21 (21.6)
 4 17 (17.5)
 5 10 (10.3)
 ≥ 6 16 (16.5)